Operating Income: The income after operating expenses.
Monte Rosa Therapeutics, Inc. (GLUE) had Operating Income of $-49.72M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$2.78M |
|
$-46.13M |
|
-- |
|
$2.78M |
|
$52.50M |
|
|
Operating Income |
$-49.72M |
$3.64M |
|
$-46.08M |
|
$-46.08M |
|
$-46.13M |
|
$-46.13M |
|
$-46.13M |
|
$-46.14M |
|
$-49.72M |
|
$-47.63M |
|
83.07M |
|
83.07M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$393.19M |
|
$25.99M |
|
$55.47M |
|
$448.66M |
|
$64.21M |
|
-- |
|
$151.39M |
|
$215.60M |
|
$233.06M |
|
$233.06M |
|
$233.06M |
|
65.54M |
|
| Cash Flow Statement Financials | |
$-22.80M |
|
$-101.83M |
|
$30.35M |
|
$229.12M |
|
$134.84M |
|
$-94.28M |
|
$18.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1787.67% |
|
-1787.67% |
|
-- |
|
-1656.82% |
|
-1658.94% |
|
$-27.50M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.24 |
|
375.40 |
|
-19.80% |
|
-19.80% |
|
-10.28% |
|
-19.80% |
|
$3.56 |
|
$-0.33 |
|
$-0.27 |
|